Table 3 Epidemiologic profile and clinical characteristics
Demographic and clinical parameters | All patients (n = 74) | Died patients (n = 43) | Alive patients (n = 31) | p-value |
|---|---|---|---|---|
Sex (male/female) | 48/26 | 27/16 | 21/10 | 0.66 |
Age (years), mean/range | 61/23–88 | 64/23–88 | 48/45–78 | 0.001* |
Time from onset of symptoms* to brain imaging (days) mean/range | 2/1–4 | 2/1–4 | 2/1–4 | 0.58 |
Clinical characteristics | ||||
History of smoking | 34 | 23 (67.6%) | 11 (32.3%) | 0.125 |
Obesity | 12 | 10 (83.3%) | 2 (16.7%) | 0.053 |
ARDS | 60 | 29 (48.3%) | 31 (51.7%) | 0.0004* |
Medical history | 59 | 40 (93.02%) | 19 (61.3%) | 0.0008* |
Previous neurological illness | 17 | 8 (47.1%) | 9 (52.9%) | 0.292 |
Follow-up by CT after 2 days | 9 | 4 (44.4%) | 5 (55.6%) | 0.375 |
Clinical manifestation | ||||
Impaired consciousness | 22 | 11 (50%) | 11 (50%) | 0.357 |
Neurological findings | ||||
Infarction | 40 | 23 (57.5%) | 17 (42.5%) | 0.908 |
Hemorrhage and hematomas | 19 | 12 (63.2%) | 7 (36.8%) | 0.604 |
PRES | 3 | 0 (0.0) | 3 (100%) | 0.037* |
Cerebral edema | 2 | 1 (50%) | 1 (50%) | 0.813 |
WM leucoencephalopathy-related COVID-19 | 3 | 2 (66.7%) | 1 (33.3%) | 0.759 |
Microhemorrhage | 3 | 3 (100%) | 0 (0.0) | 0.259 |
Vascular thrombosis | 2 | 0 (0.0) | 2 (100%) | 0.172 |
Acute necrotizing encephalitis | 2 | 2 (100%) | 0 (0.0) | 0.506 |
Admission period | ||||
11–20 days | 24 | 16 (66.7%) | 8 (33.3%) | 0.301 |